| Similar Articles |
|---|
 |
BusinessWeek
August 7, 2006
Gene G. Marcial |
Emisphere Dances With Giants Tiny biotech Emisphere Technologies has attracted Big Pharma to team up on its products still in clinical trials.   |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
The Motley Fool
June 30, 2009
Brian Orelli |
Following the Pack to Future Returns Mylan's playing catch up, but there's room for more. |
The Motley Fool
September 20, 2005
Brian Gorman |
Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note. |
The Motley Fool
March 3, 2009
Brian Orelli |
Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think. |
The Motley Fool
February 7, 2005
Brian Gorman |
Alkermes Is Coming of Age The drug delivery company may soon have its own drug on the market. |
The Motley Fool
September 30, 2009
Brian Orelli |
Less Is More for Novartis That makes it simple enough. |
The Motley Fool
September 23, 2008
Brian Lawler |
Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
Managed Care
September 2003
Thomas Morrow |
Managed Care Strategy: Create Competition In Expanding Biotech Field The biotech field is booming, and insurers are scrambling to find ways to deal with the high costs of new "biologic" treatments. One strategy is to try to create more competition among the producers of biotech drugs. |
The Motley Fool
June 11, 2009
Brian Orelli |
The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics. |
The Motley Fool
June 26, 2009
Brian Orelli |
Novartis Leads the Pack Biosimilars come to Japan; will the U.S. be next? In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given. |
The Motley Fool
February 13, 2009
Brian Orelli |
The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them. |
Chemistry World
December 2007
Derek Lowe |
Column: In the Pipeline The challenge of biologics. |
The Motley Fool
June 7, 2004
Brian Gorman |
Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market. |
Managed Care
August 2007 |
Headlines On Deadline ... A survey finds that many employees struggle with basic health benefit terms... Old matches new when it comes to oral diabetes drugs... |
The Motley Fool
December 9, 2009
Brian Orelli |
Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon. |
Managed Care
March 2008 |
Specialty Drug Spending to Double by 2010 Additional indications for existing products, rather than new products, account for the bulk of increased specialty drug use. |
Managed Care
March 2006 |
HMOs Want Evidence About Arthritis Drugs Long-term research needs to be done on the cost effectiveness of biologics in fighting rheumatoid arthritis before health plans can be convinced that coverage of the new agents will save money in the long run, a recent study suggests. |
The Motley Fool
December 10, 2008
Brian Orelli |
Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline. |
The Motley Fool
October 26, 2007
Brian Orelli |
Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications. |
The Motley Fool
April 17, 2006
Brian Gorman |
Novartis Presses on Biogenerics The company wins a court case that could accelerate U.S. regulations for biogenerics. Recent developments suggest Novartis' strategy may be close to paying off. Investors, take note. |
